Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
Authors' conclusion
We found that tapering to doses of >2.5 mg/day was generally effective in terms of risk of flare. Flare risk was higher when glucocorticoids were tapered to doses ≤2.5 mg/day.
Study context
- Population
- Patients with rheumatoid arthritis (RA) on bDMARDs267 with ≥ flare in case-crossover
- Participants
- 508 patients
- Comparison
- Tapering of GC to various doses
- Outcome
- Dose-response association between GC tapering and risk of flare
- Follow-up
- 6 months preceding flare
Methodological detailshazard periods: 6 months preceding flares, control periods: 6 months prior to visits without flare
- Hazard periods: 6 months preceding flares
- Control periods: 6 months prior to visits without flare
Main finding
As reported in the abstract
Flare
Adjusted odds ratio (95% CI)
Discontinuation (0 mg/day)
1.45(1.13–2.24)
0-2.5 mg/day
1.37(1.06–2.01)
Original publication
Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs). RMD Open. Published 4 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →